TEL AVIV, Israel, Dec. 22, 2016 -- Elbit Imaging Ltd. (“EI” or the “Company”) (TASE:EMITF) (NASDAQ:EMITF) announced today, further to the Company’s announcement dated August 18, 2016 regarding the Board of Directors resolution to approve new notes' Buy-Back plan of the Company's series H notes (“The Notes”) which are traded on the Tel Aviv Stock Exchange ("TASE") and to the Company’s announcement dated December 15, 2016, regarding the last Notes buyback, that the repurchases of the following Notes was executed since the 15th of December, 2016 to the date herein:
| Note | The acquiring corporation | Quantity purchased (Par value) | Weighted average price | Total amount paid (NIS) |
| Series H | Elbit Imaging Ltd. | 5,152,770 | 99 | 5,101,242 |
The entire repurchased notes since the 12th of October, 2015, as the first Notes buyback plan announcement, to the date herein:
| Note | The acquiring corporation | Quantity purchased (Par value) | Weighted average price | Total amount paid (NIS) |
| Series H | Elbit Imaging Ltd. | 150,358,103 | 92.06 | 138,389,037 |
About Elbit Imaging Ltd.
Elbit Imaging Ltd. operates in the following principal fields of business: (i) Commercial centers - initiation, construction, and sale of commercial centers and other mixed-use property projects, predominantly in the retail sector, located in Central and Eastern Europe. In certain circumstances and depending on market conditions, the Group operates and manages commercial centers prior to their sale. (ii) Hotel - operation and management of the Radisson hotel complex in Bucharest, Romania. (iii) Medical industries and devices - (a) research and development, production and marketing of magnetic resonance imaging guided focused ultrasound treatment equipment, and (b) development of stem cell population expansion technologies and stem cell therapy products for transplantation and regenerative medicine. (iv) Plots in India - plots designated for sale initially designated to residential projects.
Any forward-looking statements in our releases include statements regarding the intent, belief or current expectations of Elbit Imaging Ltd. and our management about our business, financial condition, results of operations, and its relationship with its employees and the condition of our properties. Words such as “believe,” “expect,” “intend,” “estimate” and similar expressions are intended to identify forward-looking statements but are not the exclusive means of identifying such statements. Actual results may differ materially from those projected, expressed or implied in the forward-looking statements as a result of various factors including, without limitation, a change in market conditions, a decision to deploy the cash for other business opportunities and the factors set forth in our filings with the Securities and Exchange Commission including, without limitation, Item 3.D of our annual report on Form 20-F for the fiscal year ended December 31, 2015, under the caption “Risk Factors.” Any forward-looking statements contained in our releases speak only as of the date of such release, and we caution existing and prospective investors not to place undue reliance on such statements. Such forward-looking statements do not purport to be predictions of future events or circumstances, and therefore, there can be no assurance that any forward-looking statement contained in our releases will prove to be accurate. We undertake no obligation to update or revise any forward-looking statements.
For Further Information: Company Contact Ron Hadassi Chairman of the Board of Directors Tel: +972-3-608-6048 Fax: +972-3-608-6050 [email protected]


Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
Apple Turns 50: From Garage Startup to AI Crossroads
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Bank of America's $72.5M Epstein Settlement: What You Need to Know
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 



